ReviewFrontiers in pharmacology2020
The Cross-Talk Between the Dopaminergic and the Immune System Involved in Schizophrenia.
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 3 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Effects of IL-6/IL-6R axis alterations in serum, plasma and cerebrospinal fluid with the schizophrenia: an updated review and meta-analysis of 58 studies.Molecular and cellular biochemistry · 2024Pooled it
- Comparative Analysis of the Pre- and Post-Medication Effects of Antipsychotic Agents on the Blood-Based Oxidative Stress Biomarkers in Patients with Schizophrenia: A Meta-Analysis.Current neuropharmacology · 2023Pooled it
- Linking Inflammation, Aberrant Glutamate-Dopamine Interaction, and Post-synaptic Changes: Translational Relevance for Schizophrenia and Antipsychotic Treatment: a Systematic Review.Molecular neurobiology · 2022Pooled it
- A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-naïve first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Trial
- Individualized Medication Selection and Outcome Prediction for Patients With Dementia and BPSD Based on Systemic Immune-Inflammation Index (SII): A Retrospective Case-Control Study.Actas espanolas de psiquiatria · 2026Article
- Abnormal connectivity in the fronto-striatal network in adolescent depression with psychotic symptoms.Child and adolescent psychiatry and mental health · 2026Article
- Immunomodulatory effects of amisulpride on mammalian macrophages.Irish journal of medical science · 2026Article
- Decoding psychotropic-induced metabolic disturbances: gut-brain axis, multi-omics, and nutrition-lifestyle integration.Frontiers in nutrition · 2026Review
- Antipsychotics lower peripheral markers of inflammation in drug-naïve early psychosis: a pilot study.Frontiers in psychiatry · 2026Article
- Impact of neuroinflammation on brain glutamate and dopamine signalling in schizophrenia: an update.Metabolic brain disease · 2025Review
- Comprehensive bioinformatics analysis identifies hub genes associated with immune cell infiltration in early-onset schizophrenia.BMC psychiatry · 2025Article
- Loss of the NF-κB negative regulator Pirk inBrain communications · 2025Article
- Article
- Treatment-resistant depression: molecular mechanisms and management.Molecular biomedicine · 2024Review
- Microglial responses to inflammatory challenge in adult rats altered by developmental exposure to polychlorinated biphenyls in a sex-specific manner.Neurotoxicology · 2024Article
- Hippocampal subfields in remitted schizophrenia.Journal of the Chinese Medical Association : JCMA · 2024Article
- L-DOPA regulates neuroinflammation and Aβ pathology through NEP and ADAM17 in a mouse model of AD.Molecular brain · 2024Article
- The role of the brain renin-angiotensin system in Parkinson´s disease.Translational neurodegeneration · 2024Review
- Immunomodulatory Effects of Clozapine: More Than Just a Side Effect in Schizophrenia.Current neuropharmacology · 2024Review
- Combined Predictors for the Diagnostic Transition from Acute and Transient Psychotic Disorder to Schizophrenia: A Retrospective Study.Neuropsychiatric disease and treatment · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dopamine is one of the neurotransmitters whose transmission is altered in a number of neural pathways in the brain of schizophrenic patients. Current evidence indicates that these alterations involve hyperactive dopaminergic transmission in mesolimbic areas, striatum, and hippocampus, whereas hypoactive dopaminergic transmission has been reported in the prefrontal cortex of schizophrenic patients. Consequently, schizophrenia is associated with several cognitive and behavioral alterations. Of note, the immune system has been found to collaborate with the central nervous system in a number of cognitive and behavioral functions, which are dysregulated in schizophrenia. Moreover, emerging evidence has associated schizophrenia and inflammation. Importantly, different lines of evidence have shown dopamine as a major regulator of inflammation. In this regard, dopamine might exert strong regulation in the activity, migration, differentiation, and proliferation of immune cells that have been shown to contribute to cognitive functions, including T-cells, microglial cells, and peripheral monocytes. Thereby, alterations in dopamine levels associated to schizophrenia might affect inflammatory response of immune cells and consequently some behavioral functions, including reference memory, learning, social behavior, and stress resilience. Altogether these findings support the involvement of an active cross-talk between the dopaminergic and immune systems in the physiopathology of schizophrenia. In this review we summarize, integrate, and discuss the current evidence indicating the involvement of an altered dopaminergic regulation of immunity in schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.